Validity and Reliability of the Two-minute Step Test in Hemophilia
- Sponsor
- Hasan Kalyoncu University
- Study ID
- NCT07425327
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Hemophilia
- Reliability and Validity
- Step
Eligibility Criteria
- Sex
- MALE
- Age
- 6 Years - 18 Years
- Healthy Volunteers
- Accepted
Study Details
The aim of our study was to evaluate the psychometric properties of the 2-minute step test in hemophilia patients, assess its intra-rater and inter-rater reliability, and evaluate its convergent validity and construct validity supported by measurements of gait, balance, and functionality.
Key Dates
- First listed
- Feb 20, 2026
- Start date
- Feb 25, 2026
- Status verified
- Feb 2026
- Primary completion
- Apr 25, 2026
- Completion
- Jun 25, 2026
Study Design
- Enrollment
- 35 participants (estimated)
Arms
- Arm: Hemophilia GroupThe sample population consists of hemophilia patients aged 6-18 years who are receiving outpatient treatment, who voluntarily participate in the study and who meet the inclusion criteria. An appropriate sampling method will be used in the selection of the sample.
Primary Outcome Measure
2-Minute Step Test [ Time Frame: through of the study, average 4 months ]
Central Contacts
- Tuğba GÖNEN, Asisst. Prof. Dr.505 090 58 46
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Little Rock, Arkansas
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruiting · American Thrombosis and Hemostasis Network · Phoenix, Arizona
- ATHNdataset RegistryRecruiting · American Thrombosis and Hemostasis Network · Hickory, North Carolina
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BPHASE3 · Recruiting · Sanofi · Los Angeles, California